开发一种基于亚微米乳液的输送系统,以改善乌罗氨酸A的抗炎活性
Elisabetta Esposito1, Valentyn Dzyhovskyi2, Federico Santamaria1
1Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
概括
亚微微乳液 (S-EMs) 增强了抗氧化剂和抗衰老特性的后生物质urolithin A (UroA) 的抗炎作用. 与传统悬浮剂相比,这种新的输送系统提高了UroA的生物利用性和有效性.
科学领域:
- 纳米技术和制药科学 纳米技术和制药科学
- 后生物药物输送系统 后生物药物输送系统
- 炎症和衰老研究研究
背景情况:
- 乌罗立A (UroA) 是一种后生物质,具有显著的抗氧化,抗炎和抗细胞衰老特性.
- 氨酸的高脂友性限制了其制药应用,需要改进的输送系统,以提高稳定性和生物可用性.
- 微微乳液 (S-EMs) 提供了一种有前途的方法来克服这些局限性并改善药物输送.
研究的目的:
- 设计和表征微米级乳液 (S-EMs) 用于输送urolithin A (UroA).
- 评估带有UroA的S-EMs (S-EM-UroA) 的物理化学特性,稳定性和药物释放特征.
- 为了评估S-EM-UroA与UroA悬浮剂相比,S-EM-UroA在体外细胞毒性和体内抗炎功效.
主要方法:
- 准备了19种S-EM配方,并对外观和尺寸分布进行了表征.
- 一个选定的S-EM装载了UroA,并使用包括TEM,SAXS和FT-IR在内的技术进行了进一步分析.
- 实验室药物释放,捕获效率,细胞毒性 (MTT试验) 和体内抗炎活性 (小鼠的卡拉基诱导的脚胀模型) 被评估.
主要成果:
- 带有UroA的S-EM (S-EM-UroA) 显示出适合腹腔内给药的物理化学特性,并保持了3个月的稳定性.
- 与UroA悬浮相比,S-EM-UroA在体外释放药物的速度是UroA悬浮的2.35倍,并且在高达5μM的度下没有显示细胞毒性.
- 在体内研究显示,S-EM-UroA具有剂量依赖的抗炎作用,在2 mg/kg和4 mg/kg的剂量显著降低了脚胀,而UroA悬浮和未加载的S-EM没有任何效果.
结论:
- 乌罗立A加载次微米乳液 (S-EM-UroA) 是一种有希望且有效的输送系统,可以增强UroA的全身抗炎作用.
- 与传统的UroA悬浮剂相比,S-EM配方显著提高了UroA的生物可用性和治疗疗效.
- 这些发现凸显了S-EMs作为UroA等脂性化合物的制药应用的可行策略的潜力.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
176
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
176
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.6K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.6K
01:16Bioavailability Enhancement: Drug Solubility Enhancement
204
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
204
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185